United for Newborn Screening in Europe
LAL-D Patient Organization joins the European call to strengthen newborn screening and reduce inequalities across Europe LAL-D Patient Organization is proud to have contributed to the new European position statement on newborn screening published by EURORDIS as a...
FEETEG and LAL-D Patient Oganization – Together for Research
FEETEG and LAL-D Patient Organization Renew Their Collaboration Agreement On September 3, 2026, the Spanish Foundation for the Study and Treatment of Gaucher Disease and other Lysosomal Disorders (FEETEG) and LAL-D Patient Organization officially renewed their...
TRPM2, TFEB and LAL: A New Link
New Research Identifies a Pathway Regulating Lysosomal Acid Lipase (LAL) Activity and Lysosomal Health Research into lysosomal diseases continues to advance, providing new insights into the cellular mechanisms that maintain metabolic balance. A recent study published...
The Importance of Early Diagnosis in Wolman Disease
New Publication Expands Knowledge of Wolman Disease and Reports a Novel LIPA Variant A recent article published in Frontiers in Pediatrics reports on two Chinese infants diagnosed with Wolman Disease, the most severe infantile form of Lysosomal Acid Lipase...
